

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Familial aggregation of FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC in families with severe, early onset COPD

D L DeMeo, V J Carey, H A Chapman, J J Reilly, L C Ginns, F E Speizer, S T Weiss, E K Silverman

Thorax 2004;59:396-400. doi: 10.1136/thx.2003.012856

See end of article for authors' affiliations

Correspondence to:
Dr D L DeMeo, Channing Laboratory, Pulmonary & Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, 181 Longwood Ave, Boston, MA 02115, USA; redld@channing.harvard.edu

Received 10 July 2003
Accepted
10 December 2003

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality in the United States. Although cigarette smoking is the major risk factor for COPD, the variable development of COPD in smokers and the occasional development of COPD in non-smokers suggest that influences other than cigarette smoking are probably important. Genetic contributions to pulmonary function have been supported by both studies in the general population¹ and twin studies.²⁻⁴

Familial aggregation of and genetic contributions to COPD, a disease characterised by obstructive abnormalities in pulmonary function, have been extensively investigated. Several early studies showed an increased prevalence of airflow obstruction in first degree relatives of individuals with COPD compared with control subjects.⁵⁻⁷ More recently, our group has investigated the risk of airflow obstruction in first degree relatives of probands with severe early onset COPD.⁸ An overall decrement in forced expiratory volume in 1 second (FEV₁) was seen in current and ex-smoking first degree relatives of probands compared with control subjects, with no statistically significant difference in FEV₁ among non-smokers. McCloskey *et al* investigated the risk to siblings of COPD probands for the development of COPD, with similar findings.⁹ However, there is limited information on the heritability of flow related spirometric characteristics such as forced expiratory flow at the mid-portion of forced vital capacity (FEF₂₅₋₇₅) and FEF₂₅₋₇₅/FVC in first degree relatives of individuals with COPD. These spirometric measures may be decreased in the presence of airway abnormalities (such as those secondary to inflammation or fibrosis) or alterations in

Background: The Boston Early-Onset COPD study showed that current or ex-smoking first degree relatives of severe early onset COPD probands have significantly lower forced expiratory volume in 1 second (FEV₁) and FEV₁/forced vital capacity (FVC) values than current or ex-smoking control subjects, which suggests the existence of genetic risk factors for the development of COPD in response to cigarette smoking. We hypothesised that first degree relatives of early onset COPD probands may also have lower values of spirometric parameters such as forced expiratory flow at the mid-portion of forced vital capacity (FEF₂₅₋₇₅) and FEF₂₅₋₇₅/FVC.

Methods: Using generalised estimating equations, FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC were analysed in 333 first degree relatives of probands with severe early onset COPD and 83 population based controls; analyses were also performed on data stratified by smoking status. Narrow sense heritability estimates were calculated using a variance component approach.

Results: Significantly lower FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC were observed in smoking (FEF₂₅₋₇₅: β -0.788 l/s (95% CI -1.118 to -0.457), FEF₂₅₋₇₅/FVC: β -20.4% (95% CI -29.3 to -11.6, $p < 0.0001$ for both phenotypes) and non-smoking (FEF₂₅₋₇₅: β -0.357 l/s (95% CI -0.673 to -0.041, $p = 0.0271$), FEF₂₅₋₇₅/FVC: β -9.5% (95% CI -17.1 to -1.9, $p = 0.0145$)) first degree relatives of early onset COPD probands. Narrow sense heritability estimates for FEF₂₅₋₇₅ ($h^2 = 0.38$) and FEF₂₅₋₇₅/FVC ($h^2 = 0.45$) were similar to those for FEV₁ and FEV₁/FVC.

Conclusion: Lower values of FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC in non-smoking first degree relatives of early onset COPD probands than in controls suggest a genetic susceptibility to develop obstructive lung disease, independent of smoking, which is magnified by exposure to deleterious environments as suggested by the further decrements in FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC seen in smoking first degree relatives. FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC have high heritability and are important intermediate phenotypes for inclusion in genetic epidemiological studies of COPD.

elastic recoil; alternatively, they may indicate the presence of dysanaptic lung growth.

Identifying intermediate phenotypes other than FEV₁ and FEV₁/FVC for genetic linkage and association studies of COPD may provide further understanding of risk factors for lung function decline and genetic influences on obstructive pulmonary disease. In this study we have assessed FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC in first degree relatives of a cohort of individuals with severe early onset COPD (without severe α_1 -antitrypsin deficiency) and population based control subjects. We hypothesised that decrements in FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC may represent spirometric changes that identify individuals with an inherited susceptibility for COPD. Some of the results presented here have been reported in the preliminary form of an abstract.¹⁰

METHODS

Probands with severe early onset COPD were enrolled from pulmonary clinics at Brigham and Women's Hospital, Massachusetts General Hospital, and the Brockton/West Roxbury VA Hospital. Probands were defined as having a physician's diagnosis of COPD, FEV₁ <40% predicted, age <53 years, and no evidence of severe α_1 -antitrypsin deficiency. Potential participants were excluded from the analysis if they underwent lung transplantation before enrolment in

Abbreviations: FEF₂₅₋₇₅, forced expiratory flow at the mid-portion of forced vital capacity; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity

the study. After medical record review, 84 subjects who met the enrolment criteria were contacted by letter and enrolled as probands. First degree relatives from 77 pedigrees included parents, siblings, and children of probands with severe early onset COPD; first degree relatives were unavailable in seven other pedigrees. A more extensive description of the selection of the current cohort has been published elsewhere.⁸⁻¹¹ The present analysis excluded subjects with pulmonary function tests from outside sources.

Controls were recruited from population based studies as previously described.⁸⁻¹²⁻¹³ 169 letters were sent to subjects of similar age and sex as the study probands. Forty responses were obtained, with 33 control "probands" willing to participate. Of the 33 potential control probands, 11 were excluded because of mild smoking history and two because of scheduling difficulties. This resulted in the inclusion of 20 age, sex and smoking matched control probands, 54 of their first degree relatives and nine spouses, giving a total of 83 control individuals. Pulmonary function was not considered as part of the selection criteria for participation by controls, so all 83 controls were included in the analysis.

All participants provided written informed consent and completed a protocol that included a questionnaire, spirometric tests, and a blood specimen. The protocol was completed in the participants' homes or at the Outpatient General Clinical Research Center at Brigham and Women's Hospital. The protocol was approved by the Human Research Committee of Partners/Brigham and Women's Hospital and the Veterans' Administration Institutional Review Board.

Questionnaire

Each participant completed a modified version of the 1978 American Thoracic Society/ Division of Lung Diseases Epidemiology Questionnaire, as previously described.⁸ An "ever smoker" was defined as an individual who had smoked more than 20 packs of cigarettes in a lifetime or at least one cigarette a day for at least 1 year. A current smoker was defined as someone who answered "yes" to smoking at any time in the month before the interview. Non-smokers were classified as those who answered "no" to the question "Have you ever smoked cigarettes?" Pack years of cigarettes smoked were calculated as the product of the duration of smoking in years and the average number of cigarettes smoked per day, divided by 20 to convert to packs. Race was assessed by questionnaire (white, black, other).

Pulmonary function testing

Spirometric tests were performed for first degree relatives and control subjects with a Survey Tach spirometer (Warren

E Collins, Braintree, MA, USA) as previously described.⁸ The manoeuvres were performed in accordance with ATS criteria, with all subjects seated and wearing nose clips.¹⁴ Participants were asked to desist from using inhaled bronchodilators for 4 hours before testing, if possible. The values presented for FEV₁ represent the highest value for any effort, and FEV₁/FVC, FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC represent values from the best test effort, defined as the manoeuvre with the highest sum of FEV₁ plus FVC. Height was measured in stocking feet. Percentage predicted values were calculated using prediction equations as defined by Hankinson and colleagues.¹⁵ Pre- and post-bronchodilator (180 µg albuterol) spirometry was performed.

Statistical methods

All computations were performed with the SAS statistical package (SAS Statistical Institute, Cary, NC) on a SUN server running the UNIX operating system. The Student's *t* test was used to compare the mean values between first degree relatives and controls for unadjusted and percentage predicted pulmonary function parameters. Unadjusted values for pulmonary function parameters were considered in multivariate regression models that included age, age², sex, height, height², race, and pack years of smoking. As a number of individuals were included from each early onset COPD family and each control family, generalised estimating equation (GEE) models were used for regression. GEE models account for the positive correlation between family members within a familial cluster. Since age is an important contributor to pulmonary function outcomes, regression analyses were performed on the overall group of participants and a subset that excluded individuals 18 years or younger. Heritability estimates were computed using all individuals from the early onset COPD pedigrees. Narrow sense heritability estimates (*h*²) were calculated using a variance component approach in the SOLAR program;¹⁶ this estimate represents a ratio of the phenotypic variance due to additive genetic effects divided by the total trait phenotypic variance. The heritability estimates were calculated with inclusion of age, sex, race, height, pack years of cigarettes, pack years², age², and height² as covariates.

RESULTS

Demographic and spirometric data of first degree relatives stratified by smoking status

As previously reported, the probands with early onset COPD had severe airflow obstruction¹¹ (mean FEV₁ among probands of 16.1% predicted for men and 17.5% predicted for women). Most of the early onset COPD probands were female

Table 1 Baseline demographic and pulmonary data stratified by smoking status

	Non-smokers		p value	Smokers		p value
	First degree relatives (n = 132)	Controls (n = 35)		First degree relatives (n = 201)	Controls (n = 48)	
F/M	83/49	18/17		102/99	29/19	
Mean (range) age*	35.2 (7.8-80.0)	39.9 (19.5-84.3)	0.175	45.8 (15.1-87.0)	48.6 (18.5-83.4)	0.290
Race (white/black)	126/6	35/0		200/1	48/0	
Pack years smoking†	0	0		28.1 (25.3)	22.1 (22.1)	0.132
FEV ₁ (% predicted)†	93.90 (12.51)	93.81 (13.24)	0.973	76.74 (22.67)	89.21 (14.42)	<0.0001
FVC (% predicted)†	99.70 (11.26)	96.44 (13.54)	0.149	88.31 (17.51)	92.02 (9.94)	0.053
FEV ₁ /FVC†	77.98 (7.32)	78.78 (6.97)	0.560	68.38 (14.07)	76.76 (8.55)	<0.0001
FEF ₂₅₋₇₅ (% predicted)†	76.02 (24.52)	82.99 (26.33)	0.143	54.70 (29.96)	77.90 (35.57)	<0.0001
FEF ₂₅₋₇₅ /FVC†	72.05 (24.12)	77.15 (24.01)	0.267	51.58 (27.50)	70.34 (26.91)	<0.0001

*When 22 non-smoking and two smoking first degree relatives aged 18 years or younger were removed from the analysis the means and age ranges were 39.9 (18.3-80.0) for non-smokers and 46.1 (18.1-87.0) for smokers. These values were not statistically different from controls (p=0.884 for non-smokers, p=0.340 for smokers).

†Values are mean (SD).




Figure 1 Cumulative frequency histograms for FEF₂₅₋₇₅ percentage predicted in (A) current and ex-smoking first degree relatives of severe early onset COPD probands and controls and (B) non-smoking first degree relatives of severe early onset COPD probands and controls. (A) Approximately 59% of first degree relatives had percentage predicted FEF₂₅₋₇₅ of less than 80% compared with 35% for controls. (B) Approximately 55% of first degree relatives had percentage predicted FEF₂₅₋₇₅ less than 80% predicted compared with 48% for controls.

(71%).¹¹ In the current analysis, 55.6% of the first degree relatives of early onset COPD probands and 56.6% of the controls were female (table 1). There were no differences in mean ages between the first degree relatives and control group stratified by smoking status. The age range of the first degree relatives extended from 7.8 to 80 years for non-smokers and from 15.1 to 87 years for smokers. Exclusion of

22 non-smokers and two smokers aged 18 years or younger resulted in more comparable age ranges between the first degree relatives and controls.

Among the smokers, despite similar ages and mean pack years of smoking, first degree relatives had lower mean percentage predicted FEV₁ and FEF₂₅₋₇₅ values; among the smokers the unadjusted values (not shown) for FEV₁/FVC, FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC were also significantly lower in first degree relatives of early onset COPD probands. No significant differences in the mean values for unadjusted or percentage predicted FEV₁, FVC, FEV₁/FVC, FEF₂₅₋₇₅, or FEF₂₅₋₇₅/FVC values were seen in non-smoking first degree relatives compared with controls (not shown), although there was a trend towards lower values of FEF₂₅₋₇₅ percentage predicted and FEF₂₅₋₇₅/FVC in first degree relatives of early onset COPD probands. When individuals aged 18 years or younger were removed, percentage predicted FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC were significantly lower in first degree relatives than controls. Frequency histograms for FEF₂₅₋₇₅ for smoking and non-smoking first degree relatives and controls demonstrate these trends (fig 1).

Multivariate regression models for pulmonary function outcomes

To assess familial aggregation of FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC in smokers, multivariate regression was performed using the unadjusted spirometric values in GEE models which included the usual covariates for which pulmonary function measures are adjusted (height, age, race, sex). When multivariate models were analysed with pulmonary function phenotypes as continuous outcomes in all subjects (not stratified by smoking status), first degree relatives of early onset COPD probands had lower values than controls for FEV₁, FEF₂₅₋₇₅, and FEF₂₅₋₇₅/FVC (table 2); there was no significant difference for adjusted FVC. In current or former cigarette smokers there were also statistically significant decrements in FEV₁, FEF₂₅₋₇₅, and FEF₂₅₋₇₅/FVC among the first degree relatives (table 2). Inclusion of current smoking status in the model did not alter the trend of these findings (data not shown). In non-smokers there were no differences between first degree relatives and controls for FEV₁ and FVC. However, FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC were significantly reduced among non-smoking first degree relatives compared with non-smoking controls (table 2). Residual analysis confirmed the robust nature of these findings (data not

Table 2 Multivariate regression models for predicting pulmonary function in all subjects and after excluding those aged 18 years or younger

Outcome measure	All‡		Non-smokers‡		Smokers‡	
	β*	p value	β*	p value	β*	p value
<i>All subjects</i>						
FEV ₁ (l)	-0.214 (-0.334 to -0.093)	0.0005	-0.048 (-0.194 to 0.098)	0.5228	-0.334 (-0.496 to -0.172)	<0.0001
FVC (l)	-0.019 (-0.152 to 0.114)	0.7749	0.079 (-0.076 to 0.233)	0.3181	-0.084 (-0.256 to 0.088)	0.3363
FEF ₂₅₋₇₅ (l/s)	-0.605 (-0.855 to -0.356)	<0.0001	-0.357 (-0.673 to -0.041)	0.0271	-0.788 (-1.118 to -0.457)	<0.0001
FEF ₂₅₋₇₅ (l/s)†	-0.3499 (-0.528 to -0.172)	0.0001	-0.294 (-0.501 to -0.088)	0.0052	-0.4061 (-0.647 to -0.165)	0.0010
FEF ₂₅₋₇₅ /FVC (%)	-15.1 (-21.5 to -8.7)	<0.0001	-9.5 (-17.1 to -1.9)	0.0145	-20.4 (-29.3 to -11.6)	<0.0001
FEF ₂₅₋₇₅ /FVC (%)†	-11.2 (-17.1 to -5.2)	0.0002	-8.7 (-15.5 to -2.0)	0.0113	-13.7 (-21.9 to -5.5)	0.0011
<i>Excluding subjects aged 18 years and younger</i>						
FEV ₁ (l)	-0.197 (-0.320 to -0.073)	0.0018	-0.027 (-0.173 to 0.119)	0.7142	-0.331 (-0.493 to -0.169)	<0.0001
FVC (l)	-0.002 (-0.132 to 0.129)	0.9825	0.112 (-0.026 to 0.250)	0.1128	-0.082 (-0.254 to 0.090)	0.3487
FEF ₂₅₋₇₅ (l/s)	-0.584 (-0.844 to -0.325)	<0.0001	-0.336 (-0.666 to -0.006)	0.0463	-0.782 (-1.112 to -0.452)	<0.0001
FEF ₂₅₋₇₅ (l/s)†	-0.350 (-0.528 to -0.172)	0.0001	-0.299 (-0.503 to -0.095)	0.0040	-0.406 (-0.648 to -0.165)	0.0010
FEF ₂₅₋₇₅ /FVC (%)	-15.1 (-21.5 to -8.7)	<0.0001	-9.7 (-17.5 to -1.9)	0.0148	-20.3 (-29.2 to -11.5)	<0.0001
FEF ₂₅₋₇₅ /FVC (%)†	-11.2 (-17.0 to -5.5)	0.0001	-9.2 (-15.7 to -2.7)	0.0056	-13.7 (-21.9 to -5.5)	0.0011

*Beta values presented are the regression coefficients for first degree relatives with controls as the reference group with confidence intervals in parentheses.

†Model includes FEV₁.

‡Age, age², height, height², sex, race, and pack years in model.

Table 3 Heritability estimates for spirometric parameters

Spirometric parameter	Mean (SE) h^2 *
FEV ₁ †	0.32 (0.06)
FVC†	0.31 (0.06)
FEV ₁ /FVC†	0.31 (0.05)
FEF ₂₅₋₇₅ ‡	0.38 (0.10)
FEF ₂₅₋₇₅ /FVC‡	0.45 (0.09)

*Age, sex, race, height, pack years of cigarettes, age², height², and pack years² included as covariates in the model.

†n = 583 individuals.

‡n = 576 individuals.

shown). A sensitivity analysis excluding individuals aged 18 years or younger did not alter the overall significance of these findings in non-smokers (table 2).

Heritability of spirometric phenotypes

Heritability estimates were obtained for 576 individuals in the Boston Early-Onset COPD Study pedigrees for all spirometric parameters (table 3). Proband and all extended family members who participated in this study were included in the analysis. The heritability estimates for FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC were at least equal to those values for FEV₁ and FEV₁/FVC, with narrow sense heritability estimates for FEF₂₅₋₇₅ and for FEF₂₅₋₇₅/FVC calculated as 0.38 and 0.45, respectively.

DISCUSSION

The phenotypic expression of COPD is under both genetic and environmental influence. As a complex human disease, COPD is heterogeneous in presentation, with variable severity and anatomical distribution. To date, the only known genetic risk factor for COPD is severe α_1 -antitrypsin deficiency, and research efforts are ongoing in an attempt to localise the other genetic influences on this complex disease. From an environmental perspective, cigarette smoke exposure is an established risk factor. Proband with severe early onset COPD were culled in an effort to define other genetic factors relevant to the heritability and expression of COPD. This cohort of individuals with severe early onset COPD has disease out of proportion to age and smoking histories, suggesting the presence of an underlying susceptibility that is under genetic influence and subject to modification of phenotypic expression due to gene \times environment interactions.

Familial aggregation has previously been reported for COPD and for spirometric measures of pulmonary function. Most of the earlier investigations have focused on FEV₁ and FEV₁/FVC. The current investigation of first degree relatives of early onset COPD probands provides further insight into the familial aggregation of spirometric phenotypes. A previous analysis of spirometric phenotypes in the first 44 pedigrees of this early onset COPD cohort showed that current and ex-smoking first degree relatives had reduced FEV₁ and FEV₁/FVC compared with control subjects of similar age and smoking history.⁸ No increased risk for decrements in FEV₁ or FEV₁/FVC was seen in non-smoking first degree relatives. Identification of phenotypic characteristics that differentiate non-smokers is important as this may point to intermediate phenotypes of COPD that are under strong genetic control, as well as being potentially indicative of a susceptibility to develop clinically significant disease in the setting of an appropriate environmental exposure.

This current analysis in the Boston Early-Onset COPD Study extends the previous analysis to the flow related measures FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC, and identifies these

flow parameters as potential indicators of genetic susceptibility to develop COPD. Cohen *et al*¹⁷ have suggested familial aggregation of phenotypes related to abnormalities in forced expiration, finding differences in Vmax for lifetime non-smokers together with decrements in Vmax, V₅₀, and V₂₅ flow related measures among first degree relatives who smoked.¹⁷ Our findings are potentially suggestive of a heritable abnormality in airways development that may predispose to disease susceptibility later in life. Since these decrements are manifest in non-smokers and are of a larger magnitude in first degree relatives who smoke, our results suggest both a baseline genetic predisposition for lower FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC as well as a potential gene \times smoking interaction that accentuates the decrements in FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC. These findings remained robust after the exclusion of individuals with low FEV₁, suggesting that the observations in smokers and non-smokers are not being driven by individuals who already have low lung function. There was no change in the findings of lower spirometric measures among the smoking first degree relatives compared with controls, regardless of how smoking was considered as a covariate (current smoking, ever smoking, pack years smoked). This suggests that differential inflammatory effects of current smoking at the time of spirometry are not the explanation for our results. This study did not quantify the amount of childhood exposure to smoke experienced by first degree relatives; assessment of childhood smoke exposure is subject to potential recall bias. Adding childhood tobacco smoke exposure as a yes/no variable to our multivariate models did not change the results among the smokers or non-smokers.

Our analysis has several important limitations. The Boston Early-Onset COPD Study cohort is predominantly white, so generalisability of these findings to individuals and families of other races may be limited. The rate of recruitment among the controls was low; only 20 control probands and 83 total controls were recruited from letters sent out to individuals who had been previous participants in population based studies from our laboratory.⁸ The size of the control group is an important consideration as we interpret our findings, and a larger control group would strengthen the interpretability and generalisability of our results. Despite the potentially increased measurement related variability in FEF₂₅₋₇₅ and FEF₂₅₋₇₅/FVC, the fact that there was any difference between the non-smokers suggests that these phenotypes are important to consider in genetic epidemiology studies, even if the absolute magnitude of our findings may be influenced by the small size of our control group. The sensitivity analyses performed by removing the younger individuals suggest that our results are not being driven by a small number of younger individuals in the early onset COPD pedigrees. FEF₂₅₋₇₅ is a more variable measure than FEV₁, but the same technique and spirometric equipment were used to measure this parameter in all subjects, which may contribute to increased accuracy of measurement of these phenotypes. Lastly, we do not have longitudinal follow up data to assess the development of COPD in the first degree relatives, nor do we have radiographic correlates assessing the presence of emphysema in the first degree relatives or controls. Longitudinal investigation and confirmation of these findings in an independent cohort is a goal of future studies.

Abnormalities in FEF₂₅₋₇₅ have been considered as evidence for small airways disease,¹⁸ although other investigators have suggested that this measure does not provide information beyond FEV₁/FVC for characterising small airway disease.¹⁹⁻²¹ Alternatively, decrements in FEF₂₅₋₇₅/FVC may represent variations in lung elastic recoil or other acquired/inherited abnormalities in airway function, variability in genetically programmed responses to oxidative and

proteolytic stress in the lungs, or may be the result of airway/lung parenchyma dysanapsis. FEF_{25-75}/FVC has been used as a measure of dysanaptic lung growth, the physiologically normal but non-isotropic lung growth that occurs between the airways and lung parenchyma. Tager and colleagues have shown that FEF_{25-75}/FVC is highly correlated with Mead's earlier measures of dysanapsis (as measured by the ratio of maximal flow at 50% vital capacity \times static recoil pressure of the lung at 50% vital capacity).^{22, 23} Dysanaptic lung growth may predispose to the development of obstructive lung disease^{24, 25} and may also predict airway hyperresponsiveness.²⁶ Chen and colleagues²⁷ have recently investigated whether dysanaptic lung growth has a genetic component.²⁷ They investigated V_{max50}/FVC using segregation analysis and suggested that dysanaptic growth of the lung airways to parenchyma is under major gene control.

Although we do not currently have longitudinal follow up data on the first degree relatives of early onset COPD probands to assess the development of lung disease, it is our hypothesis that the first degree relatives of individuals with severe early onset disease who demonstrate reduced levels of spirometric flow parameters have increased susceptibility to develop airflow obstruction later in life. The decrements of FEF_{25-75} and FEF_{25-75}/FVC in non-smoking first degree relatives suggest a phenotypic difference from population based controls. This finding may be related to a baseline susceptibility to develop lung disease in families of probands with early onset COPD, with an increased risk to develop airflow obstruction in the setting of gene \times environment (smoking) interactions. Importantly, we have shown significant heritability estimates for FEF_{25-75} and FEF_{25-75}/FVC similar to those for FEV_1 and FEV_1/FVC . These findings suggest the importance of including these additional spirometric measures as intermediate phenotypes in studies of the genetic epidemiology of COPD.

In summary, investigation of the spirometric characteristics of first degree relatives of probands with severe early onset COPD unrelated to severe α_1 -antitrypsin deficiency found reductions in FEF_{25-75} and FEF_{25-75}/FVC in smoking and non-smoking first degree relatives, with heritability estimates that are comparable to FEV_1 and FEV_1/FVC . These findings suggest that genetic factors may be relevant to the determination of FEF_{25-75} and FEF_{25-75}/FVC . Since differences between non-smokers have not been demonstrated in our cohort for FEV_1 and FEV_1/FVC , this suggests that FEF_{25-75} and FEF_{25-75}/FVC may represent genetic effects that are manifest early in life and identify a disease susceptibility characteristic that is highly heritable. FEF_{25-75} and FEF_{25-75}/FVC are important intermediate phenotypes to consider in genetic linkage and association studies of COPD.

Authors' affiliations

D DeMeo, V Carey F Speizer S Weiss, E Silverman, Channing Laboratory, Brigham and Women's Hospital, Boston, MA, USA

D DeMeo, J Reilly, E Silverman, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA

D DeMeo, J Reilly, F Speizer S Weiss, E Silverman, Harvard Medical School, Boston, MA, USA

L Ginns, Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

H Chapman, Cardiovascular Research Institute, Department of Medicine, University of California at San Francisco, San Francisco, CA, USA

Dr DeMeo was supported by National Institute of Health (NIH) grant T32 HL0742722. The Boston Early-Onset COPD Study was supported by NIH grant R01 HL61575.

REFERENCES

- Lewitter FI, Tager IB, McGue M, et al. Genetic and environmental determinants of level of pulmonary function. *Am J Epidemiol* 1984;**120**:518-30.
- Redline S, Tishler PV, Rosner B, et al. Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins. *Am J Epidemiol* 1989;**129**:827-36.
- Hankins D, Drage C, Zamel N, et al. Pulmonary function in identical twins raised apart. *Am Rev Respir Dis* 1982;**125**:119-21.
- Webster PM, Lorimer EG, Man SF, et al. Pulmonary function in identical twins: comparison of nonsmokers and smokers. *Am Rev Respir Dis* 1979;**119**:223-8.
- Larson RK, Barman ML, Kueppers F, et al. Genetic and environmental determinants of chronic obstructive pulmonary disease. *Ann Intern Med* 1970;**72**:627-32.
- Kueppers F, Miller RD, Gordon H, et al. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. *Am J Med* 1977;**63**:336-42.
- Cohen BH, Ball WC Jr, Brashears S, et al. Risk factors in chronic obstructive pulmonary disease (COPD). *Am J Epidemiol* 1977;**105**:223-32.
- Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. *Am J Respir Crit Care Med* 1998;**157**:1770-8.
- McCloskey SC, Patel BD, Hinchliffe SJ, et al. Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. *Am J Respir Crit Care Med* 2001;**164**:1419-24.
- DeMeo DL, Weiss ST, Drazen JM, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease: risk to relatives for sensitive spirometric phenotypes. *Am J Hum Genet* 2002;**71**:A1176.
- Silverman EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;**162**:2152-8.
- Dockery DW, Ware JH, Ferris BG Jr, et al. Distribution of forced expiratory volume in one second and forced vital capacity in healthy, white, adult never-smokers in six U.S. cities. *Am Rev Respir Dis* 1985;**131**:511-20.
- Tager IB, Rosner B, Tishler PV, et al. Household aggregation of pulmonary function and chronic bronchitis. *Am Rev Respir Dis* 1976;**114**:485-92.
- The American Thoracic Society. Standardization of spirometry—1987 update. *Am Rev Respir Dis* 1987;**136**:1285-98.
- Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med* 1999;**159**:179-87.
- Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. *Am J Hum Genet* 1998;**62**:1198-211.
- Cohen BH, Ball WC Jr, Bias WB, et al. A genetic-epidemiologic study of chronic obstructive pulmonary disease. I. Study design and preliminary observations. *Johns Hopkins Med J* 1975;**137**:95-104.
- Cosio M, Ghezzi H, Hogg JC, et al. The relations between structural changes in small airways and pulmonary-function tests. *N Engl J Med* 1978;**298**:1277-81.
- Petty TL, Silvers GW, Stanford RE. Functional correlations with mild and moderate emphysema in excised human lungs. *Am Rev Respir Dis* 1981;**124**:700-4.
- Petty TL, Silvers GW, Stanford RE. The morphology and morphometry of small airways disease (relevance to chronic obstructive pulmonary disease). *Trans Am Clin Climatol Assoc* 1982;**94**:130-40.
- Petty TL, Silvers GW, Stanford RE. Small airway disease is associated with elastic recoil changes in excised human lungs. *Am Rev Respir Dis* 1984;**130**:42-5.
- Tager IB, Weiss ST, Munoz A, et al. Determinants of response to eucapnic hyperventilation with cold air in a population-based study. *Am Rev Respir Dis* 1986;**134**:502-8.
- Mead J. Dysanapsis in normal lungs assessed by the relationship between maximal flow, static recoil, and vital capacity. *Am Rev Respir Dis* 1980;**121**:339-42.
- Brooks LJ, Byard PJ, Helms RC, et al. Relationship between lung volume and tracheal area as assessed by acoustic reflection. *J Appl Physiol* 1988;**64**:1050-4.
- Nishimura M, Kusaka T, Kobayashi S, et al. Analysis of dysanapsis in healthy twins and sons of patients with chronic obstructive lung disease. *Nihon Kyobu Shikkan Gakkai Zasshi* 1991;**29**:40-5.
- Litonjua AA, Sparrow D, Weiss ST. The FEF_{25-75}/FVC ratio is associated with methacholine airway responsiveness. The Normative Aging Study. *Am J Respir Crit Care Med* 1999;**159**:1574-9.
- Chen Y, Dosman JA, Rennie DC, et al. Major genetic effects on airway-parenchymal dysanapsis of the lung: the Humboldt family study. *Genet Epidemiol* 1999;**16**:95-110.